Nurse Practitioner in Garfield, AR Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Ms. Kirsten Peterson Burks, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 16723 Us-62, Garfield, AR 72732 Phone: 870-736-2601 |
Alicia Marie Gates, DNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 16723 Highway 62, Garfield, AR 72732 Phone: 479-359-2151 |
Taylor O Rittman, APRN Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 16723 Highway 62, Garfield, AR 72732 Phone: 877-350-8893 |
News Archive
Aggredyne closes $3 million Series A convertible preferred stock financing
Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function testing, sold out and closed a $3 million Series A convertible preferred stock financing.
Study questions value of coated, low-dose aspirin therapy
Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.
Investigational c-Met inhibitor shows early promise in NSCLC
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.
Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial
Genzyme Corporation today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.
BMEYE ccNexfin and Masimo Rainbow SET Pulse CO-Oximetry technology receive CE Mark certification
BMEYE B.V., the innovators of combined noninvasive, beat-to-beat blood pressure and cardiac output monitoring, and Masimo, the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, jointly announce today CE Mark certification and the European launch of the BMEYE ccNexfin—the first noninvasive cardiovascular monitor with Masimo Rainbow SET Pulse CO-Oximetry technology
› Verified 6 days ago